Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Hard-hitting Antibiotics May Not Prevent Evolution of Drug Resistance

February 1, 2016 10:14 am | by Penn State University | News | Comments

The standard practice of treating infections with the highest tolerable dose of antibiotic medications may not always be best way of preventing the evolution of drug resistance, a new study suggests. Read more...

TOPICS:

Zika Not Likely to Affect Large Parts of U.S., Medical Geographer Says

February 1, 2016 9:42 am | by University at Buffalo | News | Comments

There's no reason to suspect Zika will be much different from dengue fever, and those outbreaks in the United States have been pretty locally contained, according to Jared Aldstadt, University at Buffalo associate professor of geography in the College of Arts and Sciences. Read more...

TOPICS:

Brains with Schizophrenia Vary Depending on Type of Schizophrenia

February 1, 2016 9:37 am | by University of Grenada | News | Comments

An international team, made up of researchers from the University of Granada, Washington University in St. Louis, and the University of South Florida, has linked the symptoms of schizophrenia with the anatomical characteristics of the brain, by employing magnetic resonance imaging (MRI). Read more...

TOPICS:
Advertisement

Britain Approves Controversial Gene-editing Technique

February 1, 2016 9:27 am | by Maria Cheng, AP Medical Writer | News | Comments

Britain's fertility regulator has approved a scientist's request to edit the human genetic code in an effort to fight inherited diseases - but critics fear the new technique crosses too many ethical boundaries. Read more...

TOPICS:

New Biomarker to Assess Stem Cells Developed

February 1, 2016 9:18 am | by University College London | News | Comments

A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). Read more...

TOPICS:

Life at Zika Epicenter a Struggle for Afflicted Family

February 1, 2016 9:17 am | by Mauricio Savarese and Jenny Barchfield, Associated Press | News | Comments

Around the fifth month of her pregnancy, Daniele Ferreira dos Santos fell ill with a high fever and angry red splotches on her skin. Read more....

TOPICS:

Multiple Sclerosis Drug Tied to Rising JC Virus Antibody Levels

January 29, 2016 10:16 am | by American Academy of Neurology | News | Comments

People who take the drug natalizumab for multiple sclerosis may have up to a 10 times greater risk of developing a risk biomarker for activity of a virus that can lead to an often fatal brain disease, according to a study published in the January 27, 2016, online issue of Neurology Neuroimmunology and Neuroinflammation, a medical journal of the American Academy of Neurology. Read more...

TOPICS:

Tresiba: Lower Rate of Hypoglycemia Than Insulin Glargine In Phase 3b Trial

January 29, 2016 10:12 am | News | Comments

Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomized, double-blind, cross-over, treat-to-target trials, comparing the safety and efficacy of Tresiba (insulin degludec) and insulin glargine. The overall purpose of the trial was to compare the hypoglycemia occurrence in people with type 2 diabetes treated with Tresiba or insulin glargine.  Read more...

TOPICS:
Advertisement

New Therapy Halts Progression of Lou Gehrig's Disease in Mice

January 29, 2016 10:07 am | by Oregon State University | News | Comments

Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, for nearly two years in one type of mouse model used to study the disease - allowing the mice to approach their normal lifespan. Read more...

TOPICS:

Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for MDD

January 29, 2016 10:03 am | News | Comments

Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for adjunctive treatment of Major Depressive Disorder (MDD). This follows the Fast Track Designation for rapastinel granted by the FDA in 2014. Read more...

TOPICS:

FDA OKs Merck Hepatitis C Drug, Adding to Patient Choices

January 29, 2016 9:57 am | by Linda A. Johnson, AP Business Writer | News | Comments

Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck. Read more...

TOPICS:

Drug Discovery Spotlight: Zika Virus 'Spreading Explosively;' Theranos Lab in 'Immediate Jeopardy;' Depression Screenings

January 29, 2016 9:27 am | by Stephanie Guzowski, Editor | News | Comments

Welcome to Drug Discovery Spotlight, where we’ve rounded up this week’s top news, trending headlines, and all-around interesting reads.

TOPICS:

New Molecular Profiling for Glioma

January 29, 2016 8:35 am | by University of Sao Paulo | News | Comments

DNA methylation is a biochemical reaction frequently found in cancer cells that prevents the activation of the gene next to it. Read more...

TOPICS:

Finding the Right Anti-Clotting Drug for You

January 29, 2016 8:30 am | by Kumamoto University | News | Comments

A new blood clotting analysis system designed in Japan makes it easier to determine the effects of taking one or more anti-clotting drugs. Read more...

TOPICS:

U.S. Official Sees Zika Vaccine Trials Starting By End of 2016

January 29, 2016 8:22 am | by Julie Steenhuysen, Reuters | News | Comments

The United States has two potential candidates for a vaccine for the Zika virus and may begin clinical trials in people by the end of this year. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading